Too bad we don't have any connections to Pfizer!
I LIED!
Look at the IBOX above!
W. Lloyd Sanders assumed responsibility as COO in April 2008 after heading Genta's sales & marketing and worldwide commercial operations for 2 years. Prior to joining Genta, Mr. Sanders held key senior leadership positions in the commercial organizations of Pharmacia (now Pfizer), Sano-Synthelabo and subsequently Sano-Aventis. He served at the Vice-President level within the Oncology commercial organizations of Sano-Aventis and Sano-Synthelabo. In those roles, he had key responsibilities for the commercial success of Eloxatin® (oxaliplatin), Taxotere® (docetaxel), Anzemet® (dolasetron mesylate), and ELITEK® (rasburicase). He led the successful restructuring, integration, deployment, strategic development, and tactical execution of the merged companies' sales forces. He was responsible for national account GPO contracting strategy and negotiations, and he shared responsibility for oncology sales training and sales operations. At Sano?-Synthelabo, he led the 110-member team that achieved record sales for an oncology product launch with Eloxatin® (oxaliplatin). From 1987 until 2002, Mr. Sanders held progressively increasing levels of responsibility at Pharmacia, Inc. (now Pfizer) participating in the launches of Camptosar® (irinotecan) and ELLENCE® (epirubicin). Mr. Sanders holds a Bachelor of Business Administration from Memphis State University.
Gary Siegel joined Genta in May 2003 as Director, Financial Services, was appointed Senior Director, Financial Services in April 2004 and was appointed Vice President, Finance in September 2007. During his tenure at Genta, Mr. Siegel has been accountable for the day-to-day accounting and financial operations of the Company including public and management reporting, treasury operations, planning, financial controls and compliance. Mr. Siegel became an executive officer of the Company and assumed the role of interim Principal Accounting Officer, interim Principal Financial Officer and interim Corporate Secretary, effective February 29, 2008, while the Company searches for Richard J. Moran’s successor. Prior to joining Genta, he worked for two years at Geller & Company, a private consulting firm, where he led the management reporting for a multi-billion dollar client. His twenty-two years of experience in the pharmaceutical industry include leadership roles at Warner-Lambert Company and Pfizer Inc., where he held positions of progressively increasing levels of responsibility including Director, Corporate Finance and Director, Financial Planning & Reporting.
Dr. Julian brings years of pharmaceutical industry experience to Genta with a focus in preclinical pharmaceutics, product development and drug delivery technology. He has extensive experience in the development of both small molecules and biomolecules from the preclinical lead compound stage through regulatory approval. Prior to joining Genta, he held progressively senior positions at Pfizer, Warner-Lambert, Schering Plough, and McNeil. Dr. Julian holds a B.S. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of Connecticut and is a registered pharmacist.
Dr. Yoshitsu has more than 20 years of experience in the pharmaceutical industry. Most recently, he was Vice President, Pharmaceutical Business Development and Consulting, at IMS Healthcare Consulting. Previously, Dr. Yoshitsu held a similar role at Fujitsu Consulting. Dr. Yoshitsu has also served senior corporate development roles in several biotechnology and pharmaceutical companies, including Xanthus Life Sciences, Inc., Genaera, Inc., and Sandoz, Inc. Previously, he held strategic planning roles at both Merck, Inc. and Pfizer, Inc. Dr. Yoshitsu received a Ph.D. in Japan’s Political Economy from Columbia University and a Bachelor of Arts degree in East Asian Studies from Stanford University
AI
